Forecast horizon — calibration-scored at resolution.
By 2028, flow-diverter use will extend to posterior circulation aneurysms with safety non-inferior to anterior-circulation benchmarks.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1606
By 2028, MMA embolization will be incorporated into AANS/CNS guidelines as a recommended adjunct for recurrent cSDH.
0.1762
By 2028, ≥40% of cSDH evacuations at academic centers will include adjunctive MMA embolization.
0.1810
By 2028, stent retrievers will remain first-line device class, with next-gen aspiration-plus-stent hybrids not yet unseating them in RCTs.
0.1841
By 2028, CT-perfusion will be standard at the majority of thrombectomy-capable centers, matching the EXTEND-IA selection criteria.
0.1943
The PUFS trial's stated primary conclusion — Pipeline flow-diverter achieves durable occlusion of large and giant internal carotid aneurysms. — replicates in independent cohorts.
0.2007
By 2028, late-window thrombectomy (6–24h) will be explicitly endorsed by AHA/ASA guidelines as standard-of-care in qualifying LVO patients across at least 80% of US comprehensive stroke centers.